USP22 and neoplasm: The same results are obtained in liver tumors, when suppressing USP22 increases tumor immunogenicity, encourages T cells infiltration and improves susceptibility to anti-PD-L1 immunotherapy as well as cisplatin-based chemotherapy [101].